Somaxon Hits Par With IP Suit Over Silenor Generic

Law360, New York (February 2, 2011, 8:03 PM EST) -- Somaxon Pharmaceuticals Inc. slapped Par Pharmaceutical Cos. Inc. with a patent infringement suit Wednesday over Par's bid for regulatory approval to market generic versions of Somaxon's insomnia drug Silenor.

Somaxon and patent owner ProCom One Inc. lodged their complaint against parent Par and subsidiary Par Pharmaceutical Inc. in the U.S. District Court for the District of Delaware.

The U.S. Food and Drug Administration approved the prescription sleep aid Silenor, an oral tablet formulation of doxepin, in March.

At issue is U.S. Patent Number 6,211,229, titled "Treatment...
To view the full article, register now.